Systemic Lupus Erythematosus - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Systemic Lupus Erythematosus - Pipeline Review, H1 2018’, provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

- The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects

- The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

ACEA Biosciences Inc

AiCuris GmbH & Co KG

Amgen Inc

Apellis Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Asahi Kasei Pharma Corp

Atlantic Bio Sci ...

AbbVie Inc

ACEA Biosciences Inc

AiCuris GmbH & Co KG

Amgen Inc

Apellis Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Asahi Kasei Pharma Corp

Atlantic Bio Sci LLC

Aurinia Pharmaceuticals Inc

Bio-Path Holdings Inc

Biogen Inc

Biotest AG

Boehringer Ingelheim GmbH

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Carna Biosciences Inc

Celgene Corp

Cells for Cells SA

Corestem Inc

CuraVac Inc

Deltanoid Pharmaceuticals Inc

Domainex Ltd

Eisai Co Ltd

Eli Lilly and Co

Epsilon-3 Bio Ltd

F. Hoffmann-La Roche Ltd

Galapagos NV

Genentech Inc

Genosco Inc

Genovax Srl

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Idorsia Ltd

Immungenetics AG

Immunomedics Inc

Immunwork Inc

Immupharma Plc

Invion Ltd

Janus Biotherapeutics Inc

Johnson & Johnson

K-Stemcell Co Ltd

Kezar Life Sciences Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

LSK BioPartners Inc

MedAnnex Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mount Tam Biotechnologies Inc

Nektar Therapeutics

Neovacs SA

Nippon Chemiphar Co Ltd

Novartis AG

Nuevolution AB

Omeros Corp

Pfizer Inc

Ra Pharmaceuticals Inc

RedHill Biopharma Ltd

Regen BioPharma Inc

Sarepta Therapeutics Inc

SBI Biotech Co Ltd

Takeda Pharmaceutical Co Ltd

TheraMAB LLC

UCB SA

Xencor Inc

XTL Biopharmaceuticals Ltd

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Systemic Lupus Erythematosus – Overview 7

Systemic Lupus Erythematosus – Therapeutics Development 8

Systemic Lupus Erythematosus – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 6

Systemic Lupus Erythematosus – Overview 7

Systemic Lupus Erythematosus – Therapeutics Development 8

Systemic Lupus Erythematosus – Therapeutics Assessment 24

Systemic Lupus Erythematosus – Companies Involved in Therapeutics Development 36

Systemic Lupus Erythematosus – Drug Profiles 69

Systemic Lupus Erythematosus – Dormant Projects 415

Systemic Lupus Erythematosus – Discontinued Products 422

Systemic Lupus Erythematosus – Product Development Milestones 424

Appendix 432

List of Tables

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by ACEA Biosciences Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by AiCuris GmbH & Co KG, H1 2018

Systemic Lupus Erythematosus – Pipeline by Amgen Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Apellis Pharmaceuticals Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Araim Pharmaceuticals Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Asahi Kasei Pharma Corp, H1 2018

Systemic Lupus Erythematosus – Pipeline by Atlantic Bio Sci LLC, H1 2018

Systemic Lupus Erythematosus – Pipeline by Aurinia Pharmaceuticals Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Bio-Path Holdings Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Biogen Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Biotest AG, H1 2018

Systemic Lupus Erythematosus – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Systemic Lupus Erythematosus – Pipeline by Boston Pharmaceuticals Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Bristol-Myers Squibb Co, H1 2018

Systemic Lupus Erythematosus – Pipeline by Carna Biosciences Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Celgene Corp, H1 2018

Systemic Lupus Erythematosus – Pipeline by Cells for Cells SA, H1 2018

Systemic Lupus Erythematosus – Pipeline by Corestem Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by CuraVac Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Domainex Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Eisai Co Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Eli Lilly and Co, H1 2018

Systemic Lupus Erythematosus – Pipeline by Epsilon-3 Bio Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Galapagos NV, H1 2018

Systemic Lupus Erythematosus – Pipeline by Genentech Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Genosco Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Genovax Srl, H1 2018

Systemic Lupus Erythematosus – Pipeline by Gilead Sciences Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by GlaxoSmithKline Plc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by HanAll Biopharma Co Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Idorsia Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Immungenetics AG, H1 2018

Systemic Lupus Erythematosus – Pipeline by Immunomedics Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Immunwork Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Immupharma Plc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Invion Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Janus Biotherapeutics Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Johnson & Johnson, H1 2018

Systemic Lupus Erythematosus – Pipeline by K-Stemcell Co Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Kezar Life Sciences Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Lead Discovery Center GmbH, H1 2018

Systemic Lupus Erythematosus – Pipeline by LSK BioPartners Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by MedAnnex Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by MedImmune LLC, H1 2018

Systemic Lupus Erythematosus – Pipeline by Merck & Co Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Merck KGaA, H1 2018

Systemic Lupus Erythematosus – Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Mount Tam Biotechnologies Inc, H1 2018

Systemic Lupus Erythematosus – Pipeline by Nektar Therapeutics, H1 2018

Systemic Lupus Erythematosus – Pipeline by Neovacs SA, H1 2018

Systemic Lupus Erythematosus – Pipeline by Nippon Chemiphar Co Ltd, H1 2018

Systemic Lupus Erythematosus – Pipeline by Novartis AG, H1 2018

Systemic Lupus Erythematosus – Pipeline by Nuevolution AB, H1 2018

Systemic Lupus Erythematosus – Pipeline by Omeros Corp, H1 2018

Systemic Lupus Erythematosus – Pipeline by Pfizer Inc, H1 2018

List of Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of ...

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports